Emin Baris Akin

Dr. Emin Baris Akin

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
EDErol Demir
Erol Demir
MUMurathan Uyar
Murathan Uyar
EPErgün Parmaksız
Ergün Parmaksız
ASAyse Sinangil
Ayse Sinangil
BYBerna Yelken
Berna Yelken
ATAydin Turkmen
Aydin Turkmen
Introduction: Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID‐19.Material and Methods: Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all‐cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation.Results: Forty patients were reviewed retrospectively over a follow‐up period of 32 days after being diagnosed with COVID‐19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow‐up in the intensive care unit. None of the patients developed graft loss during follow‐up.Discussion: COVID‐19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte‐depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.

12 May 2022 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
EDErol Demir
Erol Demir
ZUZuhal Atan Ucar
Zuhal Atan Ucar
HDHamad Dheir
Hamad Dheir
RDRamazan Daniş
Ramazan Daniş
BYBerna Yelken
Berna Yelken
ATAydin Turkmen
Aydin Turkmen
Background: Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods: Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results: Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47–66]), first- (56 mL/min [IQR, 51–68]), third- (51 mL/min [IQR,48–67]) and sixth-months (52 mL/min [IQR, 48–81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions: Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode.

19 December 2020 in Transplant International
Verified
Journal Article
Closed access
PDF file
EAEmin Baris Akin
Emin Baris Akin
IBIlhami Soykan Barlas
Ilhami Soykan Barlas
MDMurat Dayangac
Murat Dayangac
The introduction of laparoscopic donor nephrectomy caused a shift toward‚ left donor nephrectomy. Some centers report a significantly low rate of endoscopic right donor nephrectomy. Hand assisted retroperitoneoscopic donor nephrectomy (HARP‐DN) was introduced as a novel surgical technique, which aims to avoid intraabdominal complications. It was also reported to provide technical advantages for right‐sided DN. In this retrospective single‐center study, we evaluated the impact of HARP‐DN technique on utilization of right‐sided DNs. After the implementation of HARP‐DN on February 2009, a total of 565 DNs were performed until December 2015. The introduction of HARP‐DN technique resulted in an immediate increase in the utilization of right kidneys from 6.1% to an average of 19.6% annually. The donors ‘outcome was similar to the left‐sided and right‐sided DN groups, excluding the increased incidence of incisional hernias in left kidney donors. None of the donors developed intraabdominal complications. In conclusion, the implementation of HARP technique significantly increased the use of right sided DNs, which enables a more liberal use of donors in LDKT.

13 November 2025 in Transplant International
Verified
Journal Article
Open access
PDF file
EAEmin Baris Akin
Emin Baris Akin
TJTamara K. Jemcov
Tamara K. Jemcov
DCDavid Cucchiari
David Cucchiari
JMJan Malik
Jan Malik
GPGavin J. Pettigrew
Gavin J. Pettigrew
JRJoris I. Rotmans
Joris I. Rotmans
There is no consensus on whether to ligate or preserve uncomplicated vascular access (VA) after kidney transplantation (KT), as International Guidelines do not address this issue. Enhanced survival rates of kidney grafts may elevate the risk of cardiac morbidity and mortality due to prolonged exposure to the hemodynamic effects of arterio-venous fistulas (AVF). Although VA ligation reduces left ventricle (LV) mass, its impact on cardiovascular (CV) morbidity or mortality is unclear. High-flow VAs can complicate KT patients, and immunosuppressive medication may increase these complications. Despite preserving VA for future hemodialysis (HD) use, central catheters are used in nearly two-thirds of patients. Detecting transplant patients who can undergo AVF ligation and reconstruction when returning to HD allows for flexible decision-making with a multidisciplinary approach, personally tailored to patients at their discretion. Therefore, an algorithm involving Doppler ultrasound and cardiac evaluation is advisable.

25 January 2021 in Journal of Renal Care
Verified
Journal Article
Closed access
PDF file
NONurten Ozen
Nurten Ozen
ASAylin Aydin Sayilan
Aylin Aydin Sayilan
SSSamet Sayilan
Samet Sayilan
DMDilek Mut
Dilek Mut
EAEmin Baris Akin
Emin Baris Akin
SESuleyman T. Ecder
Suleyman T. Ecder

9 January 2026 in Transplant International
Verified
Journal Article
Open access
PDF file
EAEmin Baris Akin
Emin Baris Akin
TJTamara K. Jemcov
Tamara K. Jemcov
DCDavid Cucchiari
David Cucchiari
JMJan Malik
Jan Malik
GPGavin J. Pettigrew
Gavin J. Pettigrew
JRJoris I. Rotmans
Joris I. Rotmans
There was a mistake in Figure 2